Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.
EGFR
TKI
adenosquamous
epidermal growth factor receptor
rechallenge
tyrosine kinase inhibitor
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
pubmed:
3
11
2020
medline:
15
4
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.
Identifiants
pubmed: 33132329
doi: 10.2169/internalmedicine.5463-20
pmc: PMC8079920
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
osimertinib
3C06JJ0Z2O
ErbB Receptors
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1071Références
Lung Cancer. 2020 Aug;146:236-243
pubmed: 32590236
Mol Clin Oncol. 2019 Aug;11(2):127-131
pubmed: 31316771
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Clin Cancer Res. 2012 May 1;18(9):2443-51
pubmed: 22407829
Lung Cancer. 2016 Sep;99:31-7
pubmed: 27565910
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Oncotarget. 2016 Jun 14;7(24):35979-35988
pubmed: 27092882
Lung Cancer. 2019 Jan;127:12-18
pubmed: 30642539
Ann Transl Med. 2019 Jan;7(1):14
pubmed: 30788361
Ann Oncol. 2013 Sep;24(9):2371-6
pubmed: 23723294
Int J Clin Oncol. 2019 Jul;24(7):731-770
pubmed: 31049758
Clin Lung Cancer. 2014 Nov;15(6):411-417.e4
pubmed: 25242668
Ann Oncol. 2018 Jan 1;29(suppl_1):i1-i2
pubmed: 29462258
Cancer Sci. 2011 May;102(5):1032-7
pubmed: 21272159
Clin Drug Investig. 2018 Oct;38(10):983-987
pubmed: 30151614
J Thorac Oncol. 2013 Jan;8(1):89-95
pubmed: 23242440
Arch Bronconeumol. 2019 Nov;55(11):602-603
pubmed: 31122852
Lung Cancer. 2020 Feb;140:113-115
pubmed: 31810534